Alessio Amatu
Alessio Amatu
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Email verificata su ospedaleniguarda.it
Titolo
Citata da
Citata da
Anno
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
7082015
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
5192013
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
4962016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
4102017
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
A Amatu, A Sartore-Bianchi, S Siena
ESMO open 1 (2), e000023, 2016
2652016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
2242014
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1462015
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
1012016
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
992018
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer
A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ...
Clinical cancer research 19 (8), 2265-2272, 2013
962013
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomata, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
942015
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
892016
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
S Siena, A Sartore-Bianchi, S Lonardi, L Trusolino, C Martino, ...
Journal of Clinical Oncology 33 (15_suppl), 3508-3508, 2015
762015
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
722019
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ...
Cardiovascular and interventional radiology 32 (6), 1187-1192, 2009
712009
Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
A Amatu, K Bencardino, A Sartore-Bianchi, S Siena
Annals of translational medicine 1 (2), 2013
662013
Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors
G Poggi, P Quaretti, C Minoia, G Bernardo, MR Bonora, R Gaggeri, ...
Anticancer research 28 (6B), 3835-3842, 2008
622008
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
612017
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ...
British journal of cancer 113 (12), 1730-1734, 2015
572015
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer …
A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019
462019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20